Cargando…

1089. Evaluation of breakthrough infections in solid organ transplant recipients: the prospective CONTRAST cohort

BACKGROUND: Solid organ transplant (SOT) recipients are at higher risk than general population for complicated COVID-19 course. Moreover COVID-19 vaccination in this setting is associated with a suboptimal immune response. However, the impact of this finding on the risk of breakthrough infection (BI...

Descripción completa

Detalles Bibliográficos
Autores principales: Tazza, Beatrice, Bonazzetti, Cecilia, Caroccia, Natascia, Gibertoni, Dino, Morelli, Maria Cristina, Tamé, Mariarosa, Busutti, Marco, Potena, Luciano, Salvaterra, Elena, Gamberini, Chiara, Viale, Pierluigi, Lazzarotto, Tiziana, Giannella, Maddalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752340/
http://dx.doi.org/10.1093/ofid/ofac492.929
_version_ 1784850698212474880
author Tazza, Beatrice
Bonazzetti, Cecilia
Caroccia, Natascia
Gibertoni, Dino
Morelli, Maria Cristina
Tamé, Mariarosa
Busutti, Marco
Potena, Luciano
Salvaterra, Elena
Gamberini, Chiara
Viale, Pierluigi
Lazzarotto, Tiziana
Giannella, Maddalena
author_facet Tazza, Beatrice
Bonazzetti, Cecilia
Caroccia, Natascia
Gibertoni, Dino
Morelli, Maria Cristina
Tamé, Mariarosa
Busutti, Marco
Potena, Luciano
Salvaterra, Elena
Gamberini, Chiara
Viale, Pierluigi
Lazzarotto, Tiziana
Giannella, Maddalena
author_sort Tazza, Beatrice
collection PubMed
description BACKGROUND: Solid organ transplant (SOT) recipients are at higher risk than general population for complicated COVID-19 course. Moreover COVID-19 vaccination in this setting is associated with a suboptimal immune response. However, the impact of this finding on the risk of breakthrough infection (BI) in SOT recipients has to be yet determined. METHODS: Single-center prospective longitudinal cohort of adult SOT recipients who received three doses of mRNA COVID-19 vaccine between February and December 2021 and were followed up to March 30 2022. Patients were tested for antibody response at several timepoints (1 st dose, 2 nd dose, 3±1 month after 1 st dose, and 1 month after 3 rd dose). Main endpoints were: i) BI defined as laboratory confirmed SARS-CoV2 infection diagnosed ≥14 day after 2 nd dose; ii) positive antibody response (AbR) defined as anti-rapid binding domain titer ≥5 U/ml determined by Elecsys Anti-SARS-CoV-2 ECLIA assay (Roche Diagnostics, CH), the last available determination before BI was considered. RESULTS: Study cohort consists of 642 SOT (277 kidney, 191 liver, 144 heart, 37 lung) recipients: 63.9% males, median age 54 ± 14.5 years. Of them, 111 (17.8%) developed BI, BI rates were 19.9%, 18.1%, 15.2% and 10.8% among liver, heart, kidney and lung transplant recipients, respectively. Positive-AbR was observed in 60% of all patients, but rates varied from 8.7% to 91.3% among patients with BI and without BI, respectively. Predictors of BI infection at multivariable analysis were liver (vs. other grafts) transplant (OR 2.98, 95%CI 1.47-6.03), mycophenolate (1.63, 0.92-2.88) and steroids (1.8, 1.05- 3.33), while positive-AbR (0.61, 0.35-1.04) and age (0.97, 0.95-0.99) were protective. On the other hand, liver transplant (1.94, 1.02-3.69), time from transplant (1.09, 1.05-1.21), and Moderna vaccine (2.32, 1.46-3.70) were associated with positive-AbR, while age (0.97, 0.95-0.98), heart transplant (0.56, 0.33-0.96), mycophenolate (0.65, 0.39-1.06) and steroids (0.39, 0.23-0.65) with lower probability of positive-AbR. CONCLUSION: Although associated with positive-AbR, liver transplant and younger age were also BI predictors, suggesting the importance of social factors and the controversial role of immune monitoring. DISCLOSURES: All Authors: No reported disclosures.
format Online
Article
Text
id pubmed-9752340
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97523402022-12-16 1089. Evaluation of breakthrough infections in solid organ transplant recipients: the prospective CONTRAST cohort Tazza, Beatrice Bonazzetti, Cecilia Caroccia, Natascia Gibertoni, Dino Morelli, Maria Cristina Tamé, Mariarosa Busutti, Marco Potena, Luciano Salvaterra, Elena Gamberini, Chiara Viale, Pierluigi Lazzarotto, Tiziana Giannella, Maddalena Open Forum Infect Dis Abstracts BACKGROUND: Solid organ transplant (SOT) recipients are at higher risk than general population for complicated COVID-19 course. Moreover COVID-19 vaccination in this setting is associated with a suboptimal immune response. However, the impact of this finding on the risk of breakthrough infection (BI) in SOT recipients has to be yet determined. METHODS: Single-center prospective longitudinal cohort of adult SOT recipients who received three doses of mRNA COVID-19 vaccine between February and December 2021 and were followed up to March 30 2022. Patients were tested for antibody response at several timepoints (1 st dose, 2 nd dose, 3±1 month after 1 st dose, and 1 month after 3 rd dose). Main endpoints were: i) BI defined as laboratory confirmed SARS-CoV2 infection diagnosed ≥14 day after 2 nd dose; ii) positive antibody response (AbR) defined as anti-rapid binding domain titer ≥5 U/ml determined by Elecsys Anti-SARS-CoV-2 ECLIA assay (Roche Diagnostics, CH), the last available determination before BI was considered. RESULTS: Study cohort consists of 642 SOT (277 kidney, 191 liver, 144 heart, 37 lung) recipients: 63.9% males, median age 54 ± 14.5 years. Of them, 111 (17.8%) developed BI, BI rates were 19.9%, 18.1%, 15.2% and 10.8% among liver, heart, kidney and lung transplant recipients, respectively. Positive-AbR was observed in 60% of all patients, but rates varied from 8.7% to 91.3% among patients with BI and without BI, respectively. Predictors of BI infection at multivariable analysis were liver (vs. other grafts) transplant (OR 2.98, 95%CI 1.47-6.03), mycophenolate (1.63, 0.92-2.88) and steroids (1.8, 1.05- 3.33), while positive-AbR (0.61, 0.35-1.04) and age (0.97, 0.95-0.99) were protective. On the other hand, liver transplant (1.94, 1.02-3.69), time from transplant (1.09, 1.05-1.21), and Moderna vaccine (2.32, 1.46-3.70) were associated with positive-AbR, while age (0.97, 0.95-0.98), heart transplant (0.56, 0.33-0.96), mycophenolate (0.65, 0.39-1.06) and steroids (0.39, 0.23-0.65) with lower probability of positive-AbR. CONCLUSION: Although associated with positive-AbR, liver transplant and younger age were also BI predictors, suggesting the importance of social factors and the controversial role of immune monitoring. DISCLOSURES: All Authors: No reported disclosures. Oxford University Press 2022-12-15 /pmc/articles/PMC9752340/ http://dx.doi.org/10.1093/ofid/ofac492.929 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Tazza, Beatrice
Bonazzetti, Cecilia
Caroccia, Natascia
Gibertoni, Dino
Morelli, Maria Cristina
Tamé, Mariarosa
Busutti, Marco
Potena, Luciano
Salvaterra, Elena
Gamberini, Chiara
Viale, Pierluigi
Lazzarotto, Tiziana
Giannella, Maddalena
1089. Evaluation of breakthrough infections in solid organ transplant recipients: the prospective CONTRAST cohort
title 1089. Evaluation of breakthrough infections in solid organ transplant recipients: the prospective CONTRAST cohort
title_full 1089. Evaluation of breakthrough infections in solid organ transplant recipients: the prospective CONTRAST cohort
title_fullStr 1089. Evaluation of breakthrough infections in solid organ transplant recipients: the prospective CONTRAST cohort
title_full_unstemmed 1089. Evaluation of breakthrough infections in solid organ transplant recipients: the prospective CONTRAST cohort
title_short 1089. Evaluation of breakthrough infections in solid organ transplant recipients: the prospective CONTRAST cohort
title_sort 1089. evaluation of breakthrough infections in solid organ transplant recipients: the prospective contrast cohort
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752340/
http://dx.doi.org/10.1093/ofid/ofac492.929
work_keys_str_mv AT tazzabeatrice 1089evaluationofbreakthroughinfectionsinsolidorgantransplantrecipientstheprospectivecontrastcohort
AT bonazzetticecilia 1089evaluationofbreakthroughinfectionsinsolidorgantransplantrecipientstheprospectivecontrastcohort
AT caroccianatascia 1089evaluationofbreakthroughinfectionsinsolidorgantransplantrecipientstheprospectivecontrastcohort
AT gibertonidino 1089evaluationofbreakthroughinfectionsinsolidorgantransplantrecipientstheprospectivecontrastcohort
AT morellimariacristina 1089evaluationofbreakthroughinfectionsinsolidorgantransplantrecipientstheprospectivecontrastcohort
AT tamemariarosa 1089evaluationofbreakthroughinfectionsinsolidorgantransplantrecipientstheprospectivecontrastcohort
AT busuttimarco 1089evaluationofbreakthroughinfectionsinsolidorgantransplantrecipientstheprospectivecontrastcohort
AT potenaluciano 1089evaluationofbreakthroughinfectionsinsolidorgantransplantrecipientstheprospectivecontrastcohort
AT salvaterraelena 1089evaluationofbreakthroughinfectionsinsolidorgantransplantrecipientstheprospectivecontrastcohort
AT gamberinichiara 1089evaluationofbreakthroughinfectionsinsolidorgantransplantrecipientstheprospectivecontrastcohort
AT vialepierluigi 1089evaluationofbreakthroughinfectionsinsolidorgantransplantrecipientstheprospectivecontrastcohort
AT lazzarottotiziana 1089evaluationofbreakthroughinfectionsinsolidorgantransplantrecipientstheprospectivecontrastcohort
AT giannellamaddalena 1089evaluationofbreakthroughinfectionsinsolidorgantransplantrecipientstheprospectivecontrastcohort